11,218 Shares in Illumina, Inc. $ILMN Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,218 shares of the life sciences company’s stock, valued at approximately $1,471,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB grew its position in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after acquiring an additional 79 shares during the period. Assetmark Inc. grew its position in Illumina by 10.2% during the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 96 shares during the period. Versant Capital Management Inc grew its position in Illumina by 8.9% during the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after acquiring an additional 111 shares during the period. Archer Investment Corp grew its position in Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after acquiring an additional 123 shares during the period. Finally, Callan Family Office LLC grew its position in Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock valued at $279,000 after acquiring an additional 124 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 1.0%

NASDAQ:ILMN opened at $126.44 on Wednesday. The business’s 50-day moving average is $125.39 and its two-hundred day moving average is $123.11. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The firm has a market capitalization of $19.33 billion, a PE ratio of 23.20, a price-to-earnings-growth ratio of 2.44 and a beta of 1.49.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the company posted $0.95 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Stifel Nicolaus lifted their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. UBS Group reaffirmed a “neutral” rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. Finally, Guggenheim lifted their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.